• U.S. Centers for Medicare & Medicaid Services (CMS) confirm reimbursement for CT:VQ
• CT:VQ will be reimbursed at US$650.50 per scan under the Hospital Outpatient Prospective Payment System (OPPS)
• Reimbursement enables hospitals and imaging centres to confidently integrate CT:VQ into standard workflows

4DMedical Limited, a global leader in respiratory imaging technology, has announced that the U.S. Centers for Medicare & Medicaid Services (CMS) have confirmed reimbursement for the company's groundbreaking CT-based ventilation-perfusion software, CT:VQ. CMS has established that CT:VQ falls under Category III Current Procedural Terminology (CPT®) codes 0721T and 0722T, and will be paid at US$650.50 per scan, effective immediately. This clear reimbursement pathway is crucial for widespread market adoption, as hospitals and imaging centres can now confidently integrate this technology into their standard workflows, knowing they will receive reliable payment through established systems. The technology offers improved economics for both outpatient and inpatient settings. Under the Hospital Outpatient Prospective Payment System (OPPS), CMS will pay US$650.50 per CT:VQ scan through a New Technology APC designation, in addition to the standard chest CT scan fee, creating a predictable revenue model for providers. For inpatient settings using the Diagnosis-Related Group (DRG) payment system, CT:VQ creates opportunities to reduce costs while maintaining the highest quality care, as the technology requires no expensive new infrastructure and streamlines existing workflows. For patients, CT:VQ delivers comprehensive lung function assessment without radioactive exposure or contrast agents, using standard CT scans they may already be receiving, eliminating the need for separate nuclear medicine appointments while providing the same diagnostic information through a faster, safer procedure. This breakthrough extends advanced diagnostic capabilities to healthcare settings that previously lacked nuclear medicine facilities, improving access across diverse care environments.

With both FDA approval and Medicare reimbursement confirmed, and with its cash position now secure, 4DMedical is perfectly positioned to launch CT:VQ commercially across the United States. The company will accelerate engagements with leading hospital groups, imaging networks, and academic institutions, providing them with access to this revolutionary software that transforms a routine non-contrast CT into a powerful functional assessment.